During the reaction of antithrombin III (AT III) with target proteases the inhibitor serves as pseudo-substrate and undergoes profound conformational changes, becomes incorporated into a covalent stoichiometric enzyme-inhibitor complex which is, in contrast to native AT III, recognized by monoclonal antibody 4C9. In the absence of the target enzyme thrombin, incubation of AT III with 1–2 M guanidine, 0.6% deoxycholate, heating to 56° C, or buffer at pH 4 resulted in inactivation of the inhibitor with concomitant exposure of the epitope for 4C9 and formation of AT III multimers (from 3.9S to 7.1–7.4 S). Loss of activity, formation of multimers and exposure of neoepitope(s) of AT III occurred in a concerted fashion and followed second order kinetics with an activation energy of Ea = 31 kcal/mol. AT III-multimerization induced by treatment with 1 M guanidine (mainly AT III-tetramers with Mr of 250,000) and formation of the binary AT III-thrombin complex revealed similar self-association patterns as judged by gel electrophoresis under non-denaturing conditions. In the presence of heparin, even higher multimers of AT III-thrombin complexes were noted. Moreover, self-association products of the ternary vitronectin-thrombin-AT III complex, which is the ultimate reaction product following thrombin inhibition in the circulation, could be recognized and quantitated due to exposure of the 4C9 epitope on AT III, indicating that AT III exists in multimeric forms within binary and ternary complexes. It is proposed that the ability of these complexes to form high Mr association products is at least in part mediated by the propensity of AT III to multimerize and that multimeric forms of AT III may be involved during clearance of AT III-enzyme complexes.
References
1
Lane DA,
Caso R.
Antithrombin: Structures, genomic organization, function and inherited deficiency. Baillière Clin Haematol 1989; 2: 961-998
5
Jordan RE,
Oosta GM,
Gardner WT,
Rosenberg RD.
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090
7
Nordenman B,
Danielsson A,
Björk I.
The binding of low-affinity and high-affinity heparin to antithrombin. Fluorescence studies. Eur J Biochem 1978; 90: 1-6
9
Griffith MJ.
Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982; 257: 7360-7365
10
Amiral J,
Vissac AM,
Mimilla F,
Grosley B.
Assay of blood activation by measurement of AT III-serine esterase complexes using a specific monoclonal antibody 4C9. Thromb Haemostas 1989; 62: 479 (Abstract)
11
Jesty J.
Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III. J Biol Chem 1979; 254S: 1044-1049
14
Björk I,
Fish WW.
Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem 1982; 257: 9487-9493
15
Villanueva GB,
Allen N.
Demonstration of a two-domain structure of antithrombin III during its denaturation in guanidinium chloride. J Biol Chem 1983; 258: 11010-11013
17
Fish WW,
Danielsson A,
Nordling K,
Miller SH,
Lam CF,
Björk I.
Denaturation behavior of antithrombin in guanidinium chloride. Irreversibility of unfolding caused by aggregation. Biochemistry 1985; 24: 1510-1517
20
Danielsson A,
Björk I.
Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin. Biochem J 1983; 213: 345-353
21
Preissner KT,
Zwicker L,
Müller-Berghaus G.
Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 1987; 243: 105-111
22
Preissner KT,
Podack ER,
Müller-Eberhard HJ.
Self-association of the seventh component of human complement (C7): dimerization and polymerization. J Immunol 1985; 135: 452-458
23
Podack ER,
Tschopp J.
Polymerization of the ninth component of complement (C9): Formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA 1982; 79: 574-578
24
Preissner KT,
Podack ER,
Müller-Eberhard HJ.
The membrane attack complex of complement: relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7. J Immunol 1985; 135: 445-451
25
Tschopp J,
Müller-Eberhard HJ,
Podack ER.
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature 1982; 298: 534-538
27
Miletich JP,
Broze GJ,
Majerus PW.
Purification of human coagulation factors II, IX and X using sulfated dextran beads. Meth Enzymol 1981; 80: 221-228
28
Lundblad RL,
Uhteg LC,
Vogel CN,
Kingdon HS,
Mann KG.
Preparation and partial characterization of two forms of bovine thrombin. Biochem Biophys Res Commun 1975; 66: 482-489
29
Fenton II JW,
Fasco MJ.
Polyethylene glycol 6,000 enhancement of the clotting of fibrinogen solutions in visual and mechanical assays. Thromb Res 1974; 4: 809-817
30
Preissner KT,
Wassmuth R,
Müller-Berghaus G.
Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985; 231: 349-355
33
Dahlbäk B,
Podack ER.
Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 1985; 24: 2368-2374
34
Fraker PJ,
Speck JC.
Protein and cell membrane iodination with a sparingly soluble chloramide, l,3,4,6-tetrachloro-3a,6a-diphenyl-glycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
35
Preissner KT,
Delvos U,
Müller-Berghaus G.
Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism. Biochemistry 1987; 26S: 2521-2528
36
O’Brien RD,
Timpone CA,
Gibson RE.
The measurement of partial specific volumes and sedimentation coefficients by sucrose density centrifugation. Anal Biochem 1978; 86: 602-617
48
de Boer HC,
Preissner KT,
Bouma BN,
de Groot PG.
Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992; 267: 2264-2268
49
Perlmutter DH,
Glover GI,
Rivetna M,
Schasteen CS,
Fallon RJ.
Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 1990; 87: 3753-3757
50
Hekman CM,
Loskutoff DJ.
Bovine plasminogen activator inhibitor 1: Specificity determinations and comparion of the active, latent, and guanidine-activated forms. Biochemistry 1988; 27: 2911-2918
51
Hekman CM,
Loskutoff DJ.
Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587